<DOC>
	<DOC>NCT01892722</DOC>
	<brief_summary>To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pedaitric patients with multiple sclerosis</brief_summary>
	<brief_title>Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>diagnosis of multiple sclerosis at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0 to 5.5, inclusive patients with progressive MS patients with an active, chronic disease of the immune system other than MS patients meeting the definition of ADEM patients with severe cardiac disease or significant findings on the screening ECG. patients with severe renal insufficiency Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>